Table 1.
Distribution of baseline characteristics and outcome status in ductal and lobular carcinoma.
| Ductal carcinoma (%) | Lobular carcinoma (%) | Total | |
|---|---|---|---|
| Total n | 2604 | 561 | 3165 |
| Age at breast cancer diagnosis (years) | |||
| Median (IQRa) | 72 (64–79) | 72 (64–79) | 72(64–79) |
| 40–59 | 392 (15) | 86 (15) | 478 (15) |
| 60–69 | 785 (30) | 169 (30) | 954 (30) |
| 70–79 | 825 (32) | 177 (32) | 1002 (32) |
| 80–100 | 602 (23) | 129 (23) | 731 (23) |
| Duration of diabetes (years) | |||
| Median (IQRa) | 6.5 (3.2–10.9) | 6.5 (2.9–11.3) | 6.5(3.2–11.0) |
| 0.5–3 | 606 (23) | 142 (25) | 748 (24) |
| 3–6 | 612 (24) | 121 (22) | 733 (23) |
| 6–12 | 832 (32) | 183 (33) | 1015 (32) |
| 12–42 | 554 (21) | 115 (20) | 669 (21) |
| Prediagnostic ADM use | |||
| Metformin | 483 (19) | 105 (19) | 588 (19) |
| Otherb | 324 (12) | 78 (14) | 402 (13) |
| Metformin and otherb | 569 (22) | 114 (20) | 683 (22) |
| Insulin | 495 (19) | 105 (19) | 600 (19) |
| No history of regular ADMc use | 733 (28) | 159 (28) | 892 (28) |
| Prediagnostic statin use | |||
| Statin | 1035 (40) | 202 (36) | 1237 (39) |
| No statin | 1569 (60) | 359 (64) | 1928 (61) |
| Stage | |||
| Local | 1288 (49) | 257 (46) | 1545 (49) |
| Advanced | 1143 (44) | 259 (46) | 1402 (44) |
| Unknown | 173 (7) | 45 (8) | 218 (7) |
| Outcome at the end of follow up | |||
| Breast cancer death | 431 (17) | 113 (20) | 544 (17) |
| Other death | 688 (26) | 138 (25) | 826 (26) |
| Alive | 1485 (57) | 310 (55) | 1795 (57) |
aInterquartile range.
bOther oral antidiabetic medication.
c Antidiabetic medication.